AI assistant
Aurobindo Pharma Ltd. Earnings Release 2026
61251_rns_2026-05-21_c1a13453-bb42-4ab3-ba8d-56e2d6dafc02.pdf
Earnings Release
Open in viewerOpens in your device viewer
AUROBINDO
May 21, 2026
| To Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051 Company Code No. AUROPHARMA | To The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25^{th} floor, Dalal Street, MUMBAI -400 001 Company Code No. 524804 |
|---|---|
Dear Sir / Madam,
Sub: Press Release on Audited Financial Results of the Company for the fourth quarter and year ended March 31, 2026.
We enclose a copy of the Press Release on Audited Financial Results of the Company for the fourth quarter and year ended March 31, 2026.
Please take the information on record.
Yours faithfully,
For AUROBINDO PHARMA LIMITED
Digitally signed by ADI REDDY
BADDIGAM
Date: 2026.05.21 20:21:15 +05'30'
B. Adi Reddy
Company Secretary
Encl: as above.
AUROBINDO PHARMA LIMITED
(CIN: L24239TG1986PLC015190)
www.aurobinodo.com
Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.
Tel: +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.
Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500 038, Telangana., India. Tel: +91 40 2373 6370/ 2374 7340 Fax: +91 40 2374 1080 / 2374 6833
Email: [email protected] Website: www.aurobinodo.com
AUROBINDO PHARMA LIMITED
Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1,
Hyderabad Knowledge City, Raidurg Panmaktha,
Hyderabad – 500 032. Telangana, India
AUROBINDO
Press Release
Investor Relations | Corporate Communications
Phone: 040-66721211
Email: [email protected]
Hyderabad, India, May 21st, 2026: Aurobindo Pharma Limited (BSE: 524804 and NSE: AUROPHARMA) ("Aurobindo") today announced its consolidated financial results for the quarter and year ended March 31, 2026.
Aurobindo Pharma Limited Q4FY26
| Amount (INR Cr) | Q4 FY26 | Q4 FY25 | % Change YoY | Q3 FY26 | % Change QoQ | FY26 | FY25 | % Change YoY |
|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 8,853 | 8,382 | 5.6% | 8,646 | 2.4% | 33,653 | 31,724 | 6.1% |
| EBITDA before R&D | 2,165 | 2,202 | -1.7% | 2,163 | 0.1% | 8,340 | 8,148 | 2.4% |
| EBITDA margin before R&D | 24.5% | 26.3% | -182 bps | 25.0% | -56 bps | 24.8% | 25.7% | -90 bps |
| EBITDA | ||||||||
| (Before Forex and Other Income | ||||||||
| and exceptional Items) | 1,801 | 1,792 | 0.5% | 1,773 | 1.6% | 6,856 | 6,605 | 3.8% |
| EBITDA Margin (%) | 20.3% | 21.4% | -104 bps | 20.5% | -17 bps | 20.4% | 20.8% | -45 bps |
| PBT before share of P/L of JV | 1,293 | 1,367 | -5.4% | 1,338 | -3.4% | 5,110 | 5,098 | 0.2% |
| Net Profit for the period | 921 | 903 | 2.0% | 910 | 1.2% | 3,503 | 3,484 | 0.6% |
Key Highlights of Q4FY26
- Revenue from Operations increased by 5.6% YoY to INR 8,853 Cr with growth across businesses
- Our European business achieved a significant milestone of crossing €1bn+ in revenues in FY26, for the quarter revenues increased by 30.2% YoY to INR 2,795 Cr (EUR 261 million)
- Growth Markets revenue increased by 24.7% YoY to INR 980 Cr (USD 107 million)
- ARV revenue increased by 6.4% YoY to INR 328 Cr (USD 36 million)
- Research & Development (R&D including depreciation) spend was INR 400 Cr, 4.5% of revenues
- Received final approval for 9 ANDAs from the USFDA
- Net Profit for the quarter stood at INR 921 Cr
- Strong net cash position as on 31-Mar-26 after payment for acquisition of Khandelwal laboratories (non-oncology) business at USD 317mn
- Free Cashflows generated $35mn during the quarter
- Basic & Diluted EPS stood at INR 15.86 per share
AUROBINDO PHARMA LIMITED
Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1,
Hyderabad Knowledge City, Raidurg Panmaktha,
Hyderabad – 500 032. Telangana, India
AUROBINDO
Commenting on the Company's performance, Mr. K. Nithyananda Reddy, Vice-Chairman and Managing Director of the Company said: "We are encouraged by our performance for the quarter and the year, reflecting the resilience of our business model and the strength of our extensive product portfolio. Consistent volumes coupled with improved operating efficiencies, and disciplined execution have contributed positively to our results. With ongoing investments in capacity expansion and the stabilization of recently commercialized facilities, we remain confident in our ability to support sustainable growth and create long-term value for our stakeholders."
Operational Performance (Consolidated)
| ° Cr | Q4FY26 | Q4FY25 | Y-o-Y (%) | Q3FY26 | Q-o-Q (%) | FY26 | FY25 | Y-o-Y (%) |
|---|---|---|---|---|---|---|---|---|
| USA | 3,543 | 4,072 | -13.0% | 3,739 | -5.2% | 14,408 | 14,816 | -2.7% |
| Europe | 2,795 | 2,147 | 30.2% | 2,703 | 3.4% | 10,315 | 8,356 | 23.4% |
| Growth Markets* | 980 | 786 | 24.7% | 865 | 13.3% | 3,499 | 3,180 | 10.0% |
| ARV | 328 | 308 | 6.4% | 376 | -12.8% | 1,384 | 1,037 | 33.5% |
| Total Formulations | 7,646 | 7,313 | 4.6% | 7,683 | -0.5% | 29,606 | 27,388 | 8.1% |
| Beta-lactam | 918 | 789 | 16.3% | 731 | 25.6% | 2,972 | 3,139 | -5.3% |
| Non Beta-lactam | 290 | 280 | 3.4% | 232 | 24.8% | 1,075 | 1,184 | -9.3% |
| Total API | 1,208 | 1,069 | 12.9% | 963 | 25.4% | 4,047 | 4,323 | -6.4% |
| Puerto Rico | - | - | - | - | - | - | 13 | - |
| Revenue from operations | 8,853 | 8,382 | 5.6% | 8,646 | 2.4% | 33,653 | 31,724 | 6.1% |
*Includes domestic formulation sales of INR 76 Cr in Q4FY26 against INR 74 Cr in Q3FY26
Q4FY26: Consolidated Revenue Breakup - Geography & Business Wise
Q4FY26
AUROBINDO PHARMA LIMITED
Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1,
Hyderabad Knowledge City, Raidurg Panmaktha,
Hyderabad – 500 032. Telangana, India
AUROBINDO
FY26: Consolidated Revenue Breakup - Geography & Business Wise
FY26
Q4FY26: Business Area Wise Performance
Formulations revenue increased by 4.6% YoY to INR 7,646 Cr.
US Formulations
- US revenue decreased by 13.0% YoY to INR 3,543 Cr primarily on account of lower transient sales and accounted for 40.0% of consolidated revenue
- As on 31st March 2026, on a cumulative basis, the company has filed 888 ANDAs with USFDA and received 728 final approvals and 35 tentative approvals
- The company has launched 12 products during the quarter
Europe Formulations
- Europe revenue increased by 30.2% YoY to INR 2,795 Cr driven by robust performance across all key markets; and accounted for 31.6% of consolidated revenue
- In Euro terms, revenue increased by 10.8% YoY to EUR 261 million
AUROBINDO PHARMA LIMITED
Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1,
Hyderabad Knowledge City, Raidurg Panmaktha,
Hyderabad – 500 032. Telangana, India
AUROBINDO
Growth Markets Formulations
- Growth Markets formulations revenue increased YoY by 24.7% to INR 980 Cr driven by good performance in key markets; and accounted for 11.1% of consolidated revenue
- In USD terms, revenue increased by 18.1% YoY to USD 107 million
- Domestic formulation sales for the quarter stood at INR 76 Cr and for the full year FY26 revenues stood at INR 302 Cr
ARV Formulations
- ARV business revenue increased by 6.4% YoY to INR 328 Cr accounting for 3.7% of consolidated revenue
- In USD terms, revenue increased by 1% YoY to USD 36 million
Active Pharmaceutical Ingredients (API)
- API revenues increased by 12.9% Y-o-Y to INR 1,208 Cr contributing to 13.6% of consolidated revenue
- In USD terms, revenue increased by 6.9% to USD 132 million
Q4FY26. Global Regulatory Filings
| Details | Q4FY26 | Cumulative Filings as on 31st Mar 2026 |
|---|---|---|
| US ANDAs (including filings from Aurobindo USA) | 10 | 888 |
| US DMFs (including filings from Eugia and Auro Peptides) | 7 | 322 |
| Formulations Dossiers in other key advanced markets (incl. multiple registrations in Europe, South Africa and Canada) | 56 | 5,023 |
| API filings in other key regulated markets (incl. multiple registrations) | 39 | 4,114 |
AUROBINDO PHARMA LIMITED
Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1,
Hyderabad Knowledge City, Raidurg Panmaktha,
Hyderabad – 500 032. Telangana, India
AUROBINDO
Q4FY26: Final USFDA Approvals Received
Received by Aurobindo Pharma Limited
| # | Product | Strength | Therapy Area |
|---|---|---|---|
| 1 | Aripiprazole Orally Disintegrating Tablets USP | 10 mg and 15 mg | CENTRAL NERVOUS SYSTEM |
| 2 | Cefixime Capsules | 400 mg | ANTI-INFECTIVE |
| 3 | Bisoprolol Fumarate and Hydrochlorothiazide Tablets USP | 2.5 mg/6.25 mg, 5 mg/6.25 mg and 10 mg/6.25 mg | CARDIO-VASCULAR |
| 4 | Siponimod Tablets (FTF) | 0.25 mg, 1 mg and 2 mg | CENTRAL NERVOUS SYSTEM |
| 5 | Clindamycin Phosphate Gel USP | 1% | ANTI-INFECTIVE |
| 6 | Everolimus Tablets | 0.25 mg, 0.5 mg, 0.75 mg and 1 mg | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS |
| 7 | Citalopram Capsules | 30 mg | CENTRAL NERVOUS SYSTEM |
| 8 | Betamethasone Dipropionate Cream USP | 0.05% | STEROID (GLUCOCORTICOID) |
| 9 | Mesna Injection | 1 g/10 mL (100 mg/mL) [Multiple-Dose Vial] | CYTOPROTECTANTS |
Q4FY26: Earnings Call Details
The company will host earnings call at 8.30 AM IST on 22nd May 2026, to discuss the performance and answer any questions from participants.
To join the call through Zoom, please pre-register using the link: https://bit.ly/42COVL4
About Aurobindo Pharma Limited
Aurobindo Pharma Limited (www.auroindo.com), (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and commercializes a wide range of generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients globally in over 150 countries.
The company has 31 manufacturing and packaging facilities that are approved by leading regulatory agencies including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, Brazil ANVISA. The Company's robust product portfolio is spread over 7 major therapeutic/product areas encompassing CNS, Anti-Retroviral, CVS, Antibiotics, Gastroenterological, Anti-Diabetics and Anti-Allergic, supported by a strong R&D set-up.
For further information, please contact:
Investor Relations | Corporate Communications
Phone: 040-66721211
Email: [email protected]
Digitally signed by ADI REDDY BADDIGAM
Date: 2026.05.21 20:22:09 +05'30'